Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Frail/Elderly Metastatic NSCLC
NCT03345810Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Dec 2017
- Primary completion
- Dec 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AIO-Studien. Started Dec 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03345810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03345810.